ReviewCureus2025
Strategies for the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ): An Umbrella Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this review is to evaluate the effectiveness of different preventive strategies for medication-related osteonecrosis of the jaw (MRONJ) in at-risk patients. This umbrella review was carried out using six electronic databases: PubMed, Cochrane Library, Google Scholar, ScienceDirect, Mendeley, and Scopus. Moreover, it followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. The results of the clinical trials were described according to the PICO (Patient/Population/Problem, Intervention, Comparison, and Outcome) criteria. Prevention strategies for MRONJ discussed in the review include local preventive measures before starting antiresorptive treatment, as well as preventive measures during invasive procedures in patients undergoing antiresorptive treatment, such as temporary discontinuation of antiresorptive treatment, prophylactic antibiotic therapy, use of autologous platelet concentrates, laser therapy, surgical measures promoting healing, and, finally, the possibility of combinations of these preventive protocols. Our umbrella review does not allow us to determine the validity of the different preventive protocols for MRONJ in patients undergoing antiresorptive or anti-angiogenic treatment due to the lack of evidence in the systematic reviews included, the diversity of clinical situations, and the absence of direct comparison between the different strategies. Randomized clinical trials are needed to establish evidence-based recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.